 |
| Attached files |
| File | Filename |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R27.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R30.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R9.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R38.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R10.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R5.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R41.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R26.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R21.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R34.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R16.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R14.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R13.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R15.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R19.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R23.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R11.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R12.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R4.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R18.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R1.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R17.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R3.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R7.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R24.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R36.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R22.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R35.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R6.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R2.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R40.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R32.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R8.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R31.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R28.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R29.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R43.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | Financial_Report.xls |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R37.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R42.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R25.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R33.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R39.htm |
| EX-32.2 - EXHIBIT 32.2 - Entia Biosciences, Inc. | ex32_2apg.htm |
| EX-32.1 - EXHIBIT 32.1 - Entia Biosciences, Inc. | ex32_1apg.htm |
| EX-31.2 - EXHIBIT 31.2 - Entia Biosciences, Inc. | ex31_2apg.htm |
| EX-31.1 - EXHIBIT 31.1 - Entia Biosciences, Inc. | ex31_1apg.htm |
| 10-Q - ERGO 10-Q 09/30/12 - Entia Biosciences, Inc. | ergo10q_093012apg.htm |
v2.4.0.6
|
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
9 Months Ended |
|
Sep. 30, 2012
|
| Accounting Policies [Abstract] |
|
| Estimated Useful Lives of the Assets |
| Office equipment |
|
3 years |
| Production equipment |
|
5 to 7 years |
| Equipment under capital lease |
|
5 to 7 years |
| Leasehold improvements |
|
Lesser of lease term or useful life of improvement |
|
| Net Loss Per Common Share |
| |
|
|
For the Three Months Ended September 30, |
|
For the Nine Months Ended September 30, |
| |
|
|
2012 |
|
2011 |
|
2012 |
|
2011 |
| Numerator: |
|
|
|
|
|
|
|
|
| Net loss applicable to common shareholders |
$ (280,769) |
|
$ (200,793) |
|
$ (996,002) |
|
$ (1,094,903) |
| Denominator: |
|
|
|
|
|
|
|
|
| Weighted-average common shares outstanding |
7,209,206 |
|
6,197,676 |
|
7,190,229 |
|
6,149,050 |
| Basic and diluted net loss per share |
$ (0.04) |
|
$ (0.03) |
|
$ (0.14) |
|
$ (0.18) |
| Common stock warrants |
2,758,266 |
|
1,689,747 |
|
2,464,471 |
|
1,689,747 |
| Series A convertible preferred stock |
889,000 |
|
415,000 |
|
843,000 |
|
415,000 |
| Stock options |
|
658,240 |
|
- |
|
591,179 |
|
- |
| Convertible debt including interest |
400,025 |
|
537,865 |
|
395,624 |
|
537,865 |
| Excluded dilutive securities |
4,705,531 |
|
2,642,612 |
|
4,294,274 |
|
2,642,612 |
|
| X |
- Definition
No authoritative reference available.
+ References+ Details
| Name: |
ERGO_EstimatedUsefulLivesOfAssetsTableTextBlock |
| Namespace Prefix: |
ERGO_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_AccountingPoliciesAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations.
+ References+ Details
| Name: |
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by Entia Biosciences, Inc. and has no official or unofficial affiliation with Entia Biosciences, Inc.
Based on public records. Inadvertent errors are possible. Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|